Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial - Wikidata - awgldk - TriplyDB

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial

http://www.wikidata.org/entity/Q36933129

about

Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015 Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective Oxidative stress modulation in hepatitis C virus infected cells Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection Silymarin for HCV infection Liver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cells Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects.Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.Herb-drug interactions: challenges and opportunities for improved predictions.Hepatitis C virus and natural compounds: a new antiviral approach?Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy.Evidence for compliance with long-term medication: a systematic review of randomised controlled trials.Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis.Silymarin Constituents Enhance ABCA1 Expression in THP-1 Macrophages.Evaluating the safety and efficacy of silymarin in β-thalassemia patients: a review.Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV.Anti-hepatitis C virus activity of crude extract and fractions of Entada africana in genotype 1b replicon systems.Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication.In Vitro Study on Anti-Hepatitis C Virus Activity of Spatholobus suberectus Dunn.Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis Amelioration of bromobenzene hepatotoxicity by Withania somnifera pretreatment: Role of mitochondrial oxidative stress.Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials.In vitro studies on radioprotective efficacy of silymarin against γ-irradiation.Hepatic metabolism of licochalcone A, a potential chemopreventive chalcone from licorice (Glycyrrhiza inflata), determined using liquid chromatography-tandem mass spectrometry.Effect of Oral Silymarin Administration on Prevention of Radiotherapy Induced Mucositis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.Natural History of Hepatitis C.Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2

P2860

Q26753151-1E9753AA-5A5C-405A-91FE-89B2BCF2CD9C Q26768482-EBF3E55B-E1A9-4B44-A3AD-6495C13545B9 Q26774003-B39D320F-41D4-4EF1-9E66-CF4E4D318FFF Q26779128-C8384546-9EBF-487A-94F4-CFD4FC2911EE Q26851453-EB5B841D-CEE8-4285-BD22-10599F492D62 Q30369750-3B1C724D-C3C0-48B1-84C1-DD526B6852A5 Q36290430-A5F0BEDD-1804-4B42-829D-3561DB60CB46 Q36675737-CF3221E0-29D9-4FF4-8363-6E96E131D2BA Q36776621-65C50E02-3608-46F0-835D-A4C538A62DDE Q36910728-FAC30EA3-6546-41B2-A92E-B15E2F7B9C55 Q37399436-8F86A1AF-C456-4BA3-ACE6-57D46A66C8F0 Q37603890-992EAD17-F564-45CD-BE1F-3947CF3CA42E Q38064280-AF43F353-082B-4C51-8634-14B47312153A Q38166445-57CB4801-BBCF-4D07-AFA5-0F690DD46808 Q38167704-563C6395-6B54-4740-9D7F-B49E3C74A75B Q38326327-E970514F-B7F9-4F7E-9DF8-9D21B3681ADE Q38336287-718FF029-E797-4C5C-96A5-F69D63AE564C Q38341299-BDC761C9-E091-49D0-834A-9DDB776FC9E9 Q38735359-18DD9D97-C1D0-4198-B592-D60F5CBE59DB Q38977067-711EB225-8611-4502-9A63-9B43BF143AE0 Q39018864-F4B1E966-9B43-419A-BD38-1D654B784D44 Q40501654-707E19A2-8A27-42B2-9EF1-18FB754AF938 Q41122488-BBACDF67-EFC5-4A30-8494-89B6537340C7 Q41681218-791EABF8-F53F-4FC3-87D9-E4EA6F3AAD42 Q41729153-58862584-EE55-43F1-A178-2ADD2631322C Q44503186-556A88DE-FB04-4F77-BC18-9EDA24BFF417 Q46263528-8D6DF4C9-FA3F-4EBD-A189-CEFB82BF814B Q47640131-D1CE5E01-143B-41B0-B550-33858E2AEF8D Q48246851-627525E9-7D94-4D41-B294-94AEA4791F64 Q49835011-70159449-E200-4DEB-B19C-DA22ABD7D216 Q50934392-1986A016-CD2C-45D7-A079-9EB2BB100904 Q50947917-3B0A2E39-9530-4D6D-93F1-209AD78B777F Q58707702-250EF7AD-7589-41C3-B885-BC7BC641687C

P2860

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial

http://www.wikidata.org/entity/Q36933129

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Effect of silymarin (milk this ...... a randomized controlled trial

@en

type

label

Effect of silymarin (milk this ...... a randomized controlled trial

@en

prefLabel

Effect of silymarin (milk this ...... a randomized controlled trial

@en

P1433

Q36933129-88A30BCC-E417-437B-BE16-1A7F5C7D759E

P1476

Q36933129-23027CC6-7723-4101-9AC7-9D8F96BD2275

P2093

Q36933129-254ADFDF-8906-45CE-9DB0-298EBF29E62D

Q36933129-45F4BEFA-6712-4DB6-965E-5541FCD87A47

Q36933129-4E76774C-E71E-4898-8252-B89D7B38AD76

Q36933129-8195D1DD-03F8-4381-A727-683CFBF5491C

Q36933129-907EE0B2-D959-4558-A43B-9DB9E9A06611

Q36933129-B243DD56-0C59-456A-A932-CE45416FC264

Q36933129-B490AC4B-D0C3-4154-B754-C9CF2C009D16

P2860

Q36933129-195018D1-BF52-42A5-8C8C-D60EC417C419

Q36933129-1E895DC8-ED9D-4EA1-9D24-619FEA4E69CF

Q36933129-2034F4FC-23D6-40E3-ABB3-0AD4C492978B

Q36933129-27F4FA64-030B-40BF-907D-49A2CF5D2BED

Q36933129-38AF18D6-9FD8-4DE8-B00B-F498AFCC7ED4

Q36933129-3EFD4FE4-4170-4F08-B416-49482254E060

Q36933129-417DB892-9C1D-4158-8DA3-24CB21E49729

Q36933129-41FFABEB-B410-4E5A-BD03-F51E61A08921

Q36933129-48B8F613-C653-4779-9D87-A28DC89A31C5

Q36933129-4CC1E04A-2576-4E68-A3DC-35E42D8D5427

P304

Q36933129-D5723B10-5A5E-407A-8537-EE5FB628135E

P31

Q36933129-C5F365E7-B9BE-446C-8873-3D2960ABBC3E

P356

Q36933129-B8DA1692-626D-4A3B-B769-3BD6203E2763

P407

Q36933129-3F73D64D-495C-4FD4-9504-FFE6FA516181

P433

Q36933129-492FE48D-7B82-4FD9-9879-62A3E1184C62

P478

Q36933129-B678BEEA-F9BE-4B6D-88E2-D43DEA6492CF

P50

Q36933129-03B54664-5955-4435-AF17-39735F438BDE

Q36933129-950EEA65-6F2C-49A2-B5E4-7CDE537960AF

Q36933129-E3DEA48A-30D2-4581-8C05-44E52BF223D9

P577

Q36933129-F924813D-B6B6-4CDB-A7AD-F02321A966B5

P698

Q36933129-9DE28669-DF9A-4975-9EF3-E5E98B1EA4ED

P932

Q36933129-70882DAE-CDD6-4D50-86E7-06A5B4B64A43

P356

P1433

Journal of the American Medical Association

P1476

Effect of silymarin (milk this ...... a randomized controlled trial

@en

P2093

Catherine M Meyers

http://www.w3.org/2001/XMLSchema#string

Edward Doo

http://www.w3.org/2001/XMLSchema#string

Michael W Fried

http://www.w3.org/2001/XMLSchema#string

Roy L Hawke

http://www.w3.org/2001/XMLSchema#string

Silymarin in NASH and C Hepatitis (SyNCH) Study Group

http://www.w3.org/2001/XMLSchema#string

Steven H Belle

http://www.w3.org/2001/XMLSchema#string

Victor J Navarro

http://www.w3.org/2001/XMLSchema#string

P2860

Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases

Identification of hepatoprotective flavonolignans from silymarin

Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection

Global epidemiology of hepatitis C virus infection

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Diagnosis, management, and treatment of hepatitis C: an update

Telaprevir for previously untreated chronic hepatitis C virus infection

Boceprevir for untreated chronic HCV genotype 1 infection

Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials.

Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

P304

274-282

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2012.8265

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

308

http://www.w3.org/2001/XMLSchema#string

P50

K. Rajender Reddy

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22797645

http://www.w3.org/2001/XMLSchema#string

P932

3683986

http://www.w3.org/2001/XMLSchema#string